In vitro protein binding studies with BMS-204352: lack of protein binding displacement interaction in human serum.
BMS-204352, a maxi-K channel opener, is currently under development for the treatment of stroke. Protein binding of BMS-204352 was determined in sera from several species, namely, rat, monkey, dog, and human. Data indicated that the compound was shown to be highly protein bound in serum from all species (ca. 99.6%). In order to test for the potential for drug-drug interactions and competitive displacement of BMS-204352 by diazepam, phenytoin, propranolol, and warfarin, in vitro experiments were performed using spiked human serum and ex vivo human plasma samples. Protein binding was determined using equilibrium dialysis for 4 h at maximal therapeutic concentrations for each drug alone or in appropriate combination in spiked serum samples. Ex vivo samples from a clinical BMS-204352 study (0, 1, and 24 h) were dialyzed separately after addition of diazepam, phenytoin, propranolol, or warfarin. Drug content in biological matrices was measured for radioactivity using liquid scintillation counting. Results indicated that (1) addition of diazepam, phenytoin, propranolol, or warfarin did not alter the free fraction of BMS-204352; (2) BMS-204352 did not displace diazepam, phenytoin, propranolol, or warfarin from their protein binding sites, and (3) comparison of ex vivo plasma samples after BMS-204352 dosing indicated no impact of BMS-204352 and/or its metabolites on the free fraction of diazepam, phenytoin, propranolol, or warfarin. In conclusion, the potential for a drug-drug interaction due to alterations in protein binding with BMS-204352 is unlikely.
Krishna
R
R
Clinical Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08540, USA. rajesh.krishna@bms.com
Yao
M
M
Kaczor
D
D
Vachharajani
N
N
Srinivas
N R
NR
D000818:Animals; D001798:Blood Proteins / Q000378:metabolism*; D004285:Dogs; D004347:Drug Interactions; D006801:Humans; D007211:Indoles / Q000097:blood* / Q000493:pharmacokinetics; D008252:Macaca fascicularis; D018696:Neuroprotective Agents / Q000097:blood* / Q000493:pharmacokinetics; D011485:Protein Binding; D051381:Rats
C424388:BMS204352; D001798:Blood Proteins; D007211:Indoles; D018696:Neuroprotective Agents